tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease
PremiumCompany AnnouncementsAbivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease
1M ago
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: Market Implications
1M ago
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: A Potential Game-Changer?
Premium
Company Announcements
Abivax’s Promising Phase 2b Study on Obefazimod for Crohn’s Disease: A Potential Game-Changer?
2M ago
Abivax announces trading resumption of shares on Euronext Paris
PremiumThe FlyAbivax announces trading resumption of shares on Euronext Paris
2M ago
Abivax $400M Spot Secondary; price range $62.50-$65.00
Premium
The Fly
Abivax $400M Spot Secondary; price range $62.50-$65.00
2M ago
Abivax announces $400M ADS offering
Premium
The Fly
Abivax announces $400M ADS offering
2M ago
Abivax price target raised to $101 from $50 at Guggenheim
PremiumThe FlyAbivax price target raised to $101 from $50 at Guggenheim
2M ago
Abivax price target raised to $70 from $42 at Piper Sandler
Premium
The Fly
Abivax price target raised to $70 from $42 at Piper Sandler
2M ago
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
Premium
Ratings
Promising Phase 3 Results and Broad Market Potential Drive Buy Rating for Obefazimod
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100